1. Home
  2. PROV vs CRDF Comparison

PROV vs CRDF Comparison

Compare PROV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

HOLD

Current Price

$16.84

Market Cap

106.0M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.21

Market Cap

114.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROV
CRDF
Founded
1956
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.0M
114.2M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
PROV
CRDF
Price
$16.84
$1.21
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$16.25
$9.63
AVG Volume (30 Days)
6.1K
1.7M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
3.26%
N/A
EPS Growth
N/A
27.37
EPS
0.68
N/A
Revenue
N/A
$365,993.00
Revenue This Year
$4.14
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
$25.12
N/A
Revenue Growth
N/A
49.61
52 Week Low
$14.95
$1.16
52 Week High
$17.42
$4.56

Technical Indicators

Market Signals
Indicator
PROV
CRDF
Relative Strength Index (RSI) 57.34 34.42
Support Level $16.91 N/A
Resistance Level $17.38 $1.72
Average True Range (ATR) 0.28 0.17
MACD 0.01 -0.04
Stochastic Oscillator 78.26 7.15

Price Performance

Historical Comparison
PROV
CRDF

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: